• 1
    Solomon R, Donnenfeld ED, Azar DT, Holland EJ, Palmon FR, Pflugfelder SC, Rubenstein JB. Infectious keratitis after laser in situ keratomileusis: results of an ASCRS.Survey. J Cataract Refract Surg 2003; 29: 20012006.
  • 2
    Chang MA, Jain S, Azar DT. Infections following laser in situ keratomileusis: an integration of the published literature. Surv Ophthalmol 2004; 49: 269280.
  • 3
    Reinhard T, Knorz M, Sundmacher R. Recurrent interface infiltration with hypopyon after astigmatic laser in situ keratomileusis on a penetrating corneal graft. J Cataract Refract Surg 2004; 30: 257258.
  • 4
    Moshirfar M, Mirzaian G, Feiz V, Kang PC. Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery. J Cataract Refract Surg 2006; 32: 515518.
  • 5
    Sharma N, Sinha R, Singhvi A, Tandon R. Pseudomonas keratitis after laser in situ keratomileusis. J Cataract Refract Surg 2006; 32: 519521.
  • 6
    Vieira AC, Pereira T, de Freitas D. Late-onset infections after LASIK. J Refract Surg 2008; 24: 411413.
  • 7
    Pallikaris IG, Kalyvianaki MI, Katsanevaki VJ, Ginis HS. Epi-LASIK: preliminary clinical results of an alternative surface ablation procedure. J Cataract Refract Surg 2005; 31: 879885.
  • 8
    Gamaly TO, El Danasoury A, El Maghraby A. A prospective, randomized, contralateral eye comparison of epithelial laser in situ keratomileusis and photorefractive keratectomy in eyes prone to haze. J Refract Surg 2007; 23: S1015-S1020.
  • 9
    Smitha S, Lalitha P, Prajna VN, Srinivasan M. Susceptibility trends of pseudomonas species from corneal ulcers. Indian J Med Microbiol 2005l; 23: 168171.
  • 10
    Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 2002; 133: 463466.
  • 11
    Kowalski RP, Dhaliwal DK, Karenchak LM, Romanowski EG, Mah FS, Ritterband DC, Gordon YJ. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 2003; 136: 500505.
  • 12
    Oliveira AD, D'Azevedo PA, Francisco W. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil. Cornea 2007; 26: 194198.
  • 13
    Chaudhry NA, Tabandeh H, Rosenfeld PJ, Miller D, Davis J. Scleral buckle infection with ciprofloxacin-resistant Pseudomonas aeruginosa. Arch Ophthalmol 1998; 116: 1251.
  • 14
    Garg P, Sharma S, Rao GN. Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology 1999; 106: 13191323.
  • 15
    Giamarellos-Bourboulis EJ, Grecka P, Giamarellou H. Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multi-resistant Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 1997; 29: 8186.
  • 16
    Lang BJ, Aaron SD, Ferris W, Hebert PC, MacDonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multi-resistant strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med 2000; 162: 22412245.
  • 17
    Brown SF, Bloomfield SE, Tam WI. The cornea destroying enzyme of Pseudomonas aeruginosa. Invest Ophthalmol 1974; 13: 174180.